文献速递乳腺MR乳腺X线

治疗前MRI肿瘤特征与治疗后乳腺X线表现:能否优化MRI影像学完全缓解的乳腺癌新辅助化疗后病理完全缓解预测?

Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
PubMed 文献 · Eur Radiol · 2021-10-30

本研究回顾性评估115例新辅助化疗后MRI显示影像学完全缓解(rCR)的乳腺癌患者,分析治疗前MRI肿瘤特征及治疗后乳腺X线表现与病理完全缓解(pCR)的关系。多因素分析显示治疗前MRI多中心病灶与较低pCR几率相关(p=0.035),受体亚型仍为显著预测因子。治疗后乳腺X线残留钙化与导管原位癌相关(p=0.009),提示乳腺X线与MRI联合评估对手术规划至关重要。

要点

  • 治疗前MRI多中心病灶预示新辅助化疗后rCR患者pCR几率较低。
  • 受体亚型(HR-HER2+和三阴性)是pCR的独立预测因子。
  • 治疗后乳腺X线残留钙化与DCIS相关,需结合MRI评估。

关键影像表现/征象

  • 治疗前MRI显示多中心病灶的患者pCR几率较低(p=0.035)。
  • 肿瘤大小和形态与pCR无显著关联。
  • 治疗后乳腺X线残留钙化与DCIS相关(p=0.009)。
  • HR-HER2+和三阴性受体亚型在多变量分析中显示更高pCR几率。

诊断标准与关键数值

  • 多因素分析中治疗前MRI多中心病灶预测pCR的p值为0.035。
  • 乳腺X线残留钙化与DCIS相关性的p值为0.009。

临床应用与阅片要点

  • 对新辅助化疗后MRI显示rCR的患者,应关注治疗前MRI是否存在多中心病灶以评估pCR可能性。
  • 治疗后乳腺X线发现残留钙化需警惕DCIS可能,应结合MRI综合判断。
  • 受体亚型(HR-HER2+和三阴性)可辅助预测pCR,阅片时结合分子信息。

局限性

  • 回顾性研究设计。
  • 单中心研究。
  • 样本量有限(115例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Radiologic complete response (rCR) in breast cancer patients after neoadjuvant chemotherapy (NAC) does not necessarily correlate with pathologic complete response (pCR), a marker traditionally associated with better outcomes. We sought to verify if data extracted from two important steps of the imaging workup (tumor features at pre-treatment MRI and post-treatment mammographic findings) might assist in refining the prediction of pCR in post-NAC patients showing rCR.

METHODS: A total of 115 post-NAC women with rCR on MRI (2010-2016) were retrospectively assessed. Pre-treatment MRI (lesion morphology, size, and distribution) and post-treatment mammographic findings (calcification, asymmetry, mass, architectural distortion) were assessed, as well as clinical and molecular variables. Bivariate and multivariate analyses evaluated correlation between such variables and pCR. Post-NAC mammographic findings and their correlation with ductal in situ carcinoma (DCIS) were evaluated using Pearson's correlation.

RESULTS: Tumor distribution at pre-treatment MRI was the only significant predictive imaging feature on multivariate analysis, with multicentric lesions having lower odds of pCR (p = 0.035). There was no significant association between tumor size and morphology with pCR. Mammographic residual calcifications were associated with DCIS (p = 0.009). The receptor subtype remained as a significant predictor, with HR-HER2 + and triple-negative status demonstrating higher odds of pCR on multivariate analyses.

CONCLUSIONS: Multicentric lesions on pre-NAC MRI were associated with a lower chance of pCR in post-NAC rCR patients. The receptor subtype remained a reliable predictor of pCR. Residual mammographic calcifications correlated with higher odds of malignancy, making the correlation between mammography and MRI essential for surgical planning. Key Points • The presence of a multicentric lesion on pre-NAC MRI, even though the patient reaches a radiologic complete response on MRI, is associated with a lower chance of pCR. • Molecular status of the tumor remained the only significant predictor of pathologic complete response in such patients in the present study. • Post-neoadjuvant residual calcifications found on mammography were related to higher odds of residual malignancy, making the correlation between mammography and MRI essential for surgical planning.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Thompson BM, Chala LF, Shimizu C, et al. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI? Eur Radiol. 2021. PMID: 34716780. doi:10.1007/s00330-021-08290-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。